Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Olema Pharmaceuticals, Inc.
Report date August 01, 2024 · Filed August 05, 2024
Jointly reported with Paradigm Biocapital Advisors LP, Paradigm BioCapital Advisors GP LLC, Paradigm BioCapital International Fund Ltd.
Section 16 reporting ended · disclosed 2024-08-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectBy: Paradigm BioCapital International Fund Ltd. | 4,720,482 |
Reported balance
After 2024-08-01 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-08-01 · Sale · Disposed 1,870,499 · Balance 4,720,482 F1: These securities are held directly by Paradigm BioCapital International Fund Ltd (the "Fund"). The Fund is a private investment vehicle. Paradigm BioCapital Advisors LP (the "Adviser") is the investment adviser of the Fund. Paradigm BioCapital Advisors GP LLC (the "Adviser GP") is the general partner of the Adviser. Senai Asefaw, M.D. is the managing member of the Adviser GP. Each Reporting Person disclaims beneficial ownership of all securities reported herein, except to the extent of their pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities and Exchange Act of 1934 or for any other purpose. |
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectBy: One or more separately managed accounts | 783,118 |
Reported balance
After 2024-08-01 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2024-08-01 · Sale · Disposed 529,501 · Balance 783,118 F2: These securities are held directly by one or more separately managed accounts managed by the Adviser. Each Reporting Person disclaims beneficial ownership of all securities reported herein, except to the extent of their pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities and Exchange Act of 1934 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are held directly by Paradigm BioCapital International Fund Ltd (the "Fund"). The Fund is a private investment vehicle. Paradigm BioCapital Advisors LP (the "Adviser") is the investment adviser of the Fund. Paradigm BioCapital Advisors GP LLC (the "Adviser GP") is the general partner of the Adviser. Senai Asefaw, M.D. is the managing member of the Adviser GP. Each Reporting Person disclaims beneficial ownership of all securities reported herein, except to the extent of their pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities and Exchange Act of 1934 or for any other purpose.
F2: These securities are held directly by one or more separately managed accounts managed by the Adviser. Each Reporting Person disclaims beneficial ownership of all securities reported herein, except to the extent of their pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities and Exchange Act of 1934 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2024 Filed Aug 5, 2024 16:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock, par value $0.0001 per share | 529,501 | $14.92 | $7,897,507.42 |
DisclosureSEC source: 0001104659-24-085835 · tm2420728-1_4seq1.xml · nonDerivative · entry 2 Paradigm Biocapital Advisors LP · CIK 0001855655 · 10% owner Paradigm BioCapital Advisors GP LLC · CIK 0001994082 · 10% owner Paradigm BioCapital International Fund Ltd. · CIK 0001854392 · 10% owner Asefaw Senai · CIK 0001994183 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By: One or more separately managed accounts Disclosed balance after: 783,118 F2 · ownership.nature: These securities are held directly by one or more separately managed accounts managed by the Adviser. Each Reporting Person disclaims beneficial ownership of all securities reported herein, except to the extent of their pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities and Exchange Act of 1934 or for any other purpose. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 16:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock, par value $0.0001 per share | 1,870,499 | $14.92 | $27,898,492.59 |
DisclosureSEC source: 0001104659-24-085835 · tm2420728-1_4seq1.xml · nonDerivative · entry 1 Paradigm Biocapital Advisors LP · CIK 0001855655 · 10% owner Paradigm BioCapital Advisors GP LLC · CIK 0001994082 · 10% owner Paradigm BioCapital International Fund Ltd. · CIK 0001854392 · 10% owner Asefaw Senai · CIK 0001994183 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By: Paradigm BioCapital International Fund Ltd. Disclosed balance after: 4,720,482 F1 · ownership.nature: These securities are held directly by Paradigm BioCapital International Fund Ltd (the "Fund"). The Fund is a private investment vehicle. Paradigm BioCapital Advisors LP (the "Adviser") is the investment adviser of the Fund. Paradigm BioCapital Advisors GP LLC (the "Adviser GP") is the general partner of the Adviser. Senai Asefaw, M.D. is the managing member of the Adviser GP. Each Reporting Person disclaims beneficial ownership of all securities reported herein, except to the extent of their pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities and Exchange Act of 1934 or for any other purpose. Read SEC document |
| December 06, 2023 Filed Dec 8, 2023 16:19 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | PurchaseCommon Stock, par value $0.0001 per share | 100,000 | $11.60 | $1,160,000.00 |
DisclosureSEC source: 0001104659-23-124717 · tm2332400d1_4seq1.xml · nonDerivative · entry 1 Paradigm Biocapital Advisors LP · CIK 0001855655 · 10% owner Paradigm BioCapital Advisors GP LLC · CIK 0001994082 · 10% owner Paradigm BioCapital International Fund Ltd. · CIK 0001854392 · 10% owner Asefaw Senai · CIK 0001994183 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By: Paradigm BioCapital International Fund Ltd. Disclosed balance after: 6,590,981 F1 · ownership.nature: These securities are held directly by Paradigm BioCapital International Fund Ltd (the "Fund"). The Fund is a private investment vehicle. Paradigm BioCapital Advisors LP (the "Adviser") is the investment adviser of the Fund. Paradigm BioCapital Advisors GP LLC (the "Adviser GP") is the general partner of the Adviser. Senai Asefaw, M.D. is the managing member of the Adviser GP. Each Reporting Person disclaims beneficial ownership of all securities reported herein, except to the extent of their pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities and Exchange Act of 1934 or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.